RTTNews | Nov 30, 2021 10:34AM EST

10:33 Tuesday, November 30, 2021 (RTTNews.com) - Shares of nano-cap company Cumberland Pharmaceuticals Inc. (CPIX) more than doubled on Tuesday morning after the specialty pharmaceutical company announced that the U.S. Food and Drug Administration approved expanded labeling for Caldolor to now include use in pre-operative administration.

CPIX is currently trading at $4.4597, up $2.2597 or 102.7136%, on the Nasdaq.

FDA has now allowed the non-narcotic pain reliever to be administered just prior to surgery to enable patients to wake up from their procedure in significantly less pain.

Supporting this expanded use of Caldolor, a study of orthopedic surgical pain confirmed the significant pain reduction when the product was administered every six hours with supplemental morphine available on an as needed basis.

Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as for the reduction of fever. It was the first FDA-approved intravenous therapy for fever.

Read the original article on RTTNews ( https://www.rttnews.com/3245763/cumberland-pharmaceuticals-surges-over-100-as-fda-approves-expanded-use-of-caldolor.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved